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Introduction
Endometrial stromal sarcomas (ESS) of the
uterus are hormone-sensitive tumors. There
have been reports in the literature confirming
the  regression  of  ESS  with  progestins,
gonadotropin  analogues,  and  aromatase
inhibitors.  We  report  a  case  of  primary
extrauterine ESS of the rectovaginal septum
(RVS), which was poorly responsive and, in
fact,  progressed  on  progestin  therapy.  The
question  arises:  is  the  evident  lack  of
response  to  oral  progestin  in  our  case  an
exception or a trend more commonly seen in
primary  extrauterine,  extraovarian  ESS?  To
the best of our knowledge, there has been no
report in the literature to address this ques-
tion. Therefore, we conducted a review of the
literature to evaluate the response of these
tumors  to  hormone  therapy  in  relation  to
their estrogen and progesterone receptor sta-
tus. 
Case Report
A  45-year-old  G3P0030  African  American
woman underwent a supracervical hysterecto-
my  and  bilateral  salpingo-oophorectomy  for
chronic pelvic pain. The pathology report of
the  surgical  specimen  confirmed  the  pres-
ence  of  endometriosis.  Subsequently,  six
years later, the patient presented with vaginal
bleeding, lower abdominal pain, dyspareunia,
and difficult defecation. Vaginal examination
showed  active  bleeding  from  an  exophytic
polypoid mass in the posterior vaginal fornix.
Rectovaginal examination revealed a 4x3 cm
mass in the rectovaginal septum (RVS) and a
smooth rectal mucosa. Narrowing was noted
on  proctoscopy  at  8  cm  distance  owing  to
extrinsic  compression  from  the  mass.  The
vaginal polyp was removed and biopsies were
obtained from the adjacent normal-appearing
vaginal mucosa at the base of the mass. On
pathological examination, the lesion showed
an  overgrowth  of  endometrial-like  stromal
cells  with  scattered  benign-appearing
endometrial-type  glands.  Stromal  cells
showed mild to moderate cytological atypia.
The tumor was positive for both estrogen and
progesterone receptors. The differential diag-
nosis included polypoid endometriosis; how-
ever,  stromal  overgrowth  with  atypia  and
mitosis  favored  a  low-grade  Mullerian
adenosarcoma.  Gastrointestinal  stromal
tumor  (GIST),  though  a  strong  possibility
when masses are encountered in this loca-
tion, was ruled out effectively by morphology.
Additionally,  immunohistochemical  staining
with CD117 (not performed in our case) is
considered valuable in the diagnosis of GIST.
Given that the tumor was hormone receptor
positive,  megestrol  acetate  was  prescribed
initially for the patient in an attempt to shrink
the mass in the RVS. Despite hormone thera-
py progression of the tumor with increased
vaginal  bleeding  was  noted.  Therefore,  the
patient  underwent  a  posterior  exenteration
with end-sigmoid colostomy four months after
her initial presentation. Pathological exami-
nation revealed a low-grade endometrial stro-
mal sarcoma (ESS). Subsequently, the patient
also  received  adjuvant  radiation  because  of
copious  mucoid  material  being  present  on
debulking, and she has remained disease free
at 18 months follow-up.
Discussion
Endometrial stromal sarcoma is a rare mes-
enchymal neoplasm that usually occurs as a
primary tumor of the uterus. However, it rarely
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Table 1. Response to hormone therapy in primary extrauterine endometrial stromal sarco-
ma.
Author Site  Treatment Treatment  ER/PR status
of tumor response
*Kusaka et al. Cul-de-sac GnRH analogue, danazol Disease progression Strongly positive
Lacroix-Trilki et al. Sciatic nerve GnRH  analogue Disease progression Strongly positive
Present case Rectovaginal  Megestrol acetate Disease progression Strongly positive
septum
Only case reports of patients with extrauterine extraovarian ESS with follow-up data were included in the review. ER, estrogen receptor; PR, prog-
esterone receptor; GnRH, gonadotropin releasing hormone *High-grade tumor arising from endometriosis (all other cases had low-grade tumors).
Figure 1. High power view (magnification:
400X)  of  endometrial  stromal  sarcoma
with an entrapped benign gland (indicated
by  the  arrow)  (Stain:  hematoxylin  and
eosin.)
Figure  2.  Arrow  indicating  the  area  of
extensive  endometriosis.  (Stain:  hema-
toxylin and eosin; magnification: 200X.)[page 120] [Rare Tumors 2009; 1:e39]
Case Report
originates in sites other than the uterus and
ovaries. The role of hormone therapy is well
documented in primary low-grade ESS of the
uterus, in patients with no evidence of resid-
ual disease after surgical treatment as well as
in patients with advanced and recurrent dis-
ease. It has been shown to be effective, partic-
ularly  in  tumors  that  express  both  estrogen
and  progesterone  receptors  and  which  have
demonstrable  evidence  of  concomitant
endometriosis. Our case is unique, however,
because it was a low-grade tumor positive for
both estrogen and progesterone receptors; yet
the tumor progressed on progestin therapy. In
our  review  of  the  literature,  we  found  two
other reports (Kusaka et al.,
1 Lacroix-Triki et
al.
2)  describing  patients  with  primary
extrauterine, extraovarian ESS in whom hor-
mone  therapy  alone  was  administered.  The
treatment used and the clinical response rela-
tive to estrogen and progesterone receptor sta-
tus is summarized in Table 1.
Interestingly,  all  three  patients  (including
our case) shown in Table 1 did not respond to
hormone  therapy.  All  reported  associated
endometriosis. Two other patients
3,4 received
hormone  therapy  in  conjunction  with
chemotherapy;  however,  it  is  not  feasible  to
assess independently the role of hormone ther-
apy in these cases. One explanation for the
observed lack of response may be that, in spite
of the hormonal receptorship, not all low-grade
ESS respond to hormone therapy. Various fac-
tors have been shown to influence hormone
responsiveness:  concentration  of  the  sex
steroid receptor, and relative expression of the
progesterone  receptor  (PR)  isoforms  (PR-A
and PR-B). It is conceivable that receptor con-
centration and the predominant isoform may
vary in ESS originating in the uterus versus
extrauterine sites, such as to make the latter
less hormone responsive.
In summary, we report a trend favoring poor
responsiveness  of  extrauterine,  extraovarian
ESS  to  hormone  therapy.  This  is  significant
given the predilection to extrapolate from the
treatment responses observed in uterine ESS.
Although our conclusion is based on a limited
number of cases, our report raises an important
question that needs to be investigated further. 
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